Biotech

All Articles

Regeneron's Opdualag rival reveals 57% feedback price

.Regeneron is actually back with lasting consequence for its LAG-3 prevention and also PD-1 preventi...

AstraZeneca articles information on in-house opponents to AbbVie, Pfizer ADCs

.AstraZeneca has actually shared an early consider the efficiency of its own internal antibody-drug ...

iTeos- GSK's TIGIT celebrity presents relevant remodeling

.After introducing a stage 3 launch based on favorable midstage results, iTeos as well as GSK are ac...

More joint FDA may speed up rare condition R&ampD: record

.The FDA ought to be actually much more available as well as collective to unleash a rise in commend...

Zenas, MBX, Bicara head to Nasdaq in very hot time for biotech IPOs

.It is actually an unusually occupied Friday for biotech IPOs, with Zenas BioPharma, MBX as well as ...

Atea's COVID antiviral falls short to halt hospital stays in phase 3

.Atea Pharmaceuticals' antiviral has neglected an additional COVID-19 test, but the biotech still ke...

Neurocrine's bid to spare schizophrenia prospect stops working

.Neurocrine Biosciences' schizophrenia system pivot has actually neglected. The biotech was actually...

Sanofi pays $110M upfront for late-stage radioligand therapy

.Sanofi has brought in a late access to the radioligand event, spending 100 million euros ($ 110 tho...

F 2G raises $100M for second effort to acquire new antifungal to market

.After F2G's first effort to get a brand-new lesson of antifungal to market was actually derailed du...

Moderna targets $1.1 B in R&ampD costs slices, drops 5 programs in the middle of earnings pressures

.Moderna has vowed to cut R&ampD spending through $1.1 billion through 2027. The decision to retract...